Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.
Stocks · News reference
Entera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028
IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Half of 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Entera Bio (NASDAQ:ENTX) with a Overweight rating.
Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9
Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.